Address: Nycomed Russia-CIS ‘Fusion Park’ Business-centre 2, Bl. 1, Usatcheva Str., Moscow, 119048,Russia
Tel: +7 (495) 933-55-11
Web: http://www.takeda.com.ru/ru/
Nycomed in Russia-CIS:
The representative office of Nycomed was founded in Russia in 1993. Today Nycomed Russia-CIS is one of the leading subsidiaries of Nycomed Group. The company specializes in many therapeutic areas – neurology, cardiology, obstetrics/gynecology, endocrinology, rheumatology, pediatrics, surgery, allergology/dermatology, neonatology, general practice, and otolaryngology. Currently Nycomed is present in more than 120 cities and regions of Russia and CIS.
Nycomed global group:
We are 12,000 people, driven by a desire to help patients live full lives. Our mission is to bring medicines that make a real difference to both patients and healthcare providers. To do this, we provide medicines and products for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.
We are engaged in all aspects of a product’s life, from research and development to customer relations. We also work closely with innovative research-based companies, constantly looking for products with real promise for patients.
We believe that everything we do matters to someone. So we work carefully to make sure we get what we do right. We focus on results and respond quickly to the needs of patients and healthcare providers, giving them the best possible experience from working with us. By doing this, we can achieve our vision of being the preferred pharmaceutical company.
Based in Europe, Nycomed has a wide geographical scope. We operate extensively throughout Europe and in fast-growing markets in Latin America, Russia/CIS and Asia-Pacific.
Nycomed is privately owned and has its corporate headquarters in Zurich, Switzerland.
With a broad portfolio of products and a powerful pipeline, we work in a wide range of therapeutic areas, particularly cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management.
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Although Russian authorities received heavy criticism for approving the Sputnik V vaccine prior to the completion of Phase III clinical trials, the jab is increasingly being seen as a viable…
Russia has announced that a domestically developed COVID-19 vaccine has been approved by its health authorities, the first such approval globally. However, with large-scale Phase III trials having not yet…
Below is a selection of top stories in Russian pharma from recent months, ranging from proposed changes in legislation, labelling system updates, priorities set forth by the country’s manufacturing association…
Russia is facing a drug shortage crisis which is having a particular impact on patients with life-threatening conditions. A combination of geopolitical and bureaucratic issues are restricting the flow of…
In the latest twist in the ongoing story of Russian interference in the US presidential elections of 2016, it has emerged that Russian internet trolls and automated bots spread misinformation…
In the United States, Johnson & Johnson has an image of being very close to people. Americans grow up with this company — from baby shampoo, to Tylenol when they…
You took over this organization just three months ago, having previously headed businesses in industries as diverse as retail, food, and automobiles. What drew you to Alliance Healthcare Russia? Do…
The ARPM was founded in 2002, and you were its director from 2002-2004, before leaving for a post at the Roszdravnadzor. You’ve since rejoined as director since 2007. The organization…
When Focus Reports prepared a report on the French pharmaceutical industry in 2009/10, we found that the head of the main multinational pharmaceutical association had taken a career path quite…
The U.S. and Russia have a long history of trade, and you have personally been with the American Chamber of Commerce in Russia since 2001. Can you give a brief…
The primary objectives of this association are to promote Russia as a clinical trial destination, optimize the regulatory and legislative environment, and promote the interests of ACTO members. Can you…
You have said that AstraZeneca intends to be “in Russia for Russia” and the company has recently announced a large-scale investment in this country, financing a $150Mn domestic facility in…
See our Cookie Privacy Policy Here
